News

Blue Earth Therapeutics Awarded UK MHRA Innovation Passport for Investigational 177Lu-rhPSMA-10.1 for Treatment of Metastatic Castrate-Resistant Prostate Cancer (mCRPC)

View more

Nov 10, 2022

Nuclear medicine outlook:proven molybdenum-99 supply chain reliability and new planned capacity continue to benefit patients

View more

Nov 10, 2022

Northstar medical radioisotopes statement on current disruptions in the molybdenum-99(Mo-99)supply chain

View more

Nov 10, 2022

Kidney cancer imaging agent TLX250-CDx succeeds in phase 3 trial

View more

Nov 09, 2022

Study provides an atlas of detailed glucose uptake profiles across the human body

View more

Nov 07, 2022

Nuclear reactor inspections impact Mo-99 supplies

View more

Nov 04, 2022